ReviewInternational journal of molecular sciences2016
Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies.Translational psychiatry · 2017Pooled it
- Obesity-related differences in amygdala and hippocampal volume and metabolism before and after a placebo-controlled antidepressant trial in major depressive disorder.Scientific reports · 2026Trial
- Body mass index and atypical balance as predictors of winter depression remission in cognitive-behavioral therapy and light therapy.Journal of affective disorders · 2022Trial
- Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.Journal of clinical psychopharmacologyTrial
- Korean Medication Algorithm Project for Depressive Disorder 2025: Comparisons with Other Treatment Guidelines.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Review
- The Gender Differences of Mediating Effect of Body Mass Index Between Perceived Control and Depressive Symptoms in Korean Workers.Psychiatry investigation · 2026Article
- Appetite measures during ketamine administration in treatment-resistant mood disorders: a naturalistic study.Frontiers in nutrition · 2026Article
- Depressive Symptoms in Obese Individuals Accompanied by Greater Basal Inflammation but Lower Monocyte Inflammatory Responses to LPS: A Quest to Uncover Immunologic Links between Depression and Obesity.Neuroimmunomodulation · 2026Article
- Immune and metabolic disturbance as a function of genetic risk and phase of illness in major depression.Brain, behavior, & immunity - health · 2025Article
- Interaction between depressive state and high-fat diet and its impact on behavioral and body weight changes in male mice.Scientific reports · 2025Article
- Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- Is neuregulin-1 (NRG-1) a potential blood biomarker linking depression to obesity? A case-control study.BMC psychiatry · 2023Article
- Personalized Medicine of Omega-3 Fatty Acids in Depression Treatment in Obese and Metabolically Dysregulated Patients.Journal of personalized medicine · 2023Review
- Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients.Frontiers in genetics · 2023Article
- The selective serotonin reuptake inhibitor fluoxetine has direct effects on beta cells, promoting insulin secretion and increasing beta-cell mass.Diabetes, obesity & metabolism · 2022Article
- Neurobiological Mechanisms Modulating Emotionality, Cognition and Reward-Related Behaviour in High-Fat Diet-Fed Rodents.International journal of molecular sciences · 2022Review
- Salivary bacterial signatures in depression-obesity comorbidity are associated with neurotransmitters and neuroactive dipeptides.BMC microbiology · 2022Article
- The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Review
- Deciphering the Causal Relationships Between Low Back Pain Complications, Metabolic Factors, and Comorbidities.Journal of pain research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence regarding clinical, neurobiological, genetic, and environmental factors suggests a bidirectional link between obesity and depressive disorders. Although a few studies have investigated the link between obesity/excess body weight and the response to antidepressants in depressive disorders, the effect of weight on treatment response remains poorly understood. In this review, we summarized recent data regarding the relationship between the response to antidepressants and obesity/excess body weight in clinical studies of patients with depressive disorders. Although several studies indicated an association between obesity/excess body weight and poor antidepressant responses, it is difficult to draw definitive conclusions due to the variability of subject composition and methodological differences among studies. Especially, differences in sex, age and menopausal status, depressive symptom subtypes, and antidepressants administered may have caused inconsistencies in the results among studies. The relationship between obesity/excess body weight and antidepressant responses should be investigated further in high-powered studies addressing the differential effects on subject characteristics and treatment. Moreover, future research should focus on the roles of mediating factors, such as inflammatory markers and neurocognitive performance, which may alter the antidepressant treatment outcome in patients with comorbid obesity and depressive disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.